Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma

被引：1

作者：

Grunenberg, Alexander ^{[1
]}

Kaiser, Lisa M. ^{[2
]}

Woelfle, Stephanie ^{[2
]}

Schmelzle, Birgit ^{[2
]}

Viardot, Andreas ^{[1
]}

Moeller, Peter ^{[3
]}

Barth, Thomas F. E. ^{[3
]}

Muche, Rainer ^{[4
]}

Dreyhaupt, Jens ^{[4
]}

Buske, Christian ^{[1
]}

机构：

[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[2] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[3] Ulm Univ, Inst Pathol, Ulm, Germany

[4] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 13期

关键词：

CD20; marginal zone lymphoma; obinutuzumab; rituximab; B-CELL LYMPHOMA; MALT LYMPHOMA; CHLORAMBUCIL; RITUXIMAB; THERAPY; GA101; MONOTHERAPY; REVISION; SYSTEM;

D O I：

10.2217/fon-2020-0071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Marginal zone lymphoma (MZL) belongs to the group of indolent B-cell non-Hodgkin's lymphomas, which is characterized by an indolent course. In this mostly elderly patient population, the development of chemotherapy-free approaches is of particular interest. In this situation, single-agent treatment with the next-generation anti-CD20 antibody obinutuzumab is an attractive approach, which promises high efficacy without major toxicity. We describe here an open-label, multicentric Phase II trial evaluating the efficacy and safety of obinutuzumab in de novo MZL patients, who are treatment naive for systemic therapy and not eligible for or failed local treatment. ClinicalTrials.gov identifier NCT03322865

引用

页码：817 / 825

页数：9

共 50 条

[21] Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant
Redfield, Robert R.
Jordan, Stanley C.
Busque, Stephan
Vincenti, Flavio
Woodle, E. Steve
Desai, Niraj
Reed, Elaine F.
Tremblay, Simon
Zachary, Andrea A.
Vo, Ashley A.
Formica, Richard
Schindler, Thomas
Ha Tran
Looney, Caroline
Jamois, Candice
Green, Cherie
Morimoto, Alyssa
Rajwanshi, Richa
Schroeder, Aaron
Cascino, Matthew D.
Brunetta, Paul
Borie, Dominic
AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (11) : 3035 - 3045
[22] Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma:: a phase II study
Jäeger, G
Neumeister, P
Brezinschek, R
Höfler, G
Quehenberger, F
Linkesch, W
Sill, H
EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 69 (01) : 21 - 26
[23] Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: A meta-analysis
Teng, Siyuan
Tian, Yu
Luo, Nan
Zheng, Qiang
Shao, Mingfang
Li, Lei
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (02) : 101 - 109
[24] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment
Davis, TA
Grillo-López, AJ
White, CA
McLaughlin, P
Czuczman, MS
Link, BK
Maloney, DG
Weaver, RL
Rosenberg, J
Levy, R
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3135 - 3143
[25] Phase I/II clinical trial to evaluate the safety and efficacy of a combination of a chimeric anti-CD20 monoclonal antibody (rituximab) and G-CSF given weekly to patients with relapsed B-cell lymphoma.
vanderKolk, LE
Gerritsen, W
Baars, J
Jonkhoff, AR
vanOers, MHJ
BLOOD, 1997, 90 (10) : 2284 - 2284
[26] Anti-CD20 monoclonal antibody in autoimmune diseases
Pogliani, EM
Larocca, A
BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (07) : 350 - 351
[27] Ofatumumab, a human anti-CD20 monoclonal antibody
Osterborg, Anders
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) : 439 - 449
[28] Ofatumumab: a novel monoclonal anti-CD20 antibody
Lin, Thomas S.
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
[29] Anti-CD20 monoclonal antibody/thalidomideMyeloproliferative disorder in an elderly patient (first report with anti-CD20 monoclonal antibody): case report
Reactions Weekly, 2001, 855 (1) : 7 - 7
[30] A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
Foran, JM
Gupta, RK
Cunningham, D
Popescu, RA
Goldstone, AH
Sweetenham, JW
Pettengell, R
Johnson, PWM
Bessell, E
Hancock, B
Summers, K
Hughes, J
Rohatiner, AZS
Lister, TA
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) : 81 - 88

← 1 2 3 4 5 →